Absolutely
@BBInvestorClubThis was one of the first things I noticed about this forum: the respect investors had for management. In many posts, it was immediately distinguishable from the self-deluding praise one sees elsewhere. This was one of the many positive early signals before I dug in and started reading and absorbing all I could about the company. And then it wasn't long before the news flow started demonstrating where people's sentiment was coming from.
I believe the small minority of disparaging voices that have popped up when suspense has been high, are made up of two main varieties. People down-ramping for personal gain, and people whose trust has been violated in past investments creating a trauma that causes them to read doom into natural pauses and otherwise explicable delays. I certainly don't blame the latter group. Once bitten, twice shy. But I really hope they will start to sleep more easily at night if the upcoming news flow is positive, and I hope that their overall investment hypothesis will gradually become more sticky at the forefront of their minds. 2020 was full of terrific results for the company's pre-clinical trials, and now 2022 will be a bump year of clinical progress. This team has really excelled at developing and securing de-risked, low-hanging fruit cannabinoid combination formulation IP, addressing unmet needs with large total addressable markets. The world is about to better understand this soon.
